Miracle Mile Advisors LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Miracle Mile Advisors LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 279.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,104 shares of the biopharmaceutical company’s stock after buying an additional 25,117 shares during the period. Miracle Mile Advisors LLC’s holdings in Gilead Sciences were worth $3,786,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of GILD. Rothschild Investment LLC lifted its position in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Ignite Planners LLC boosted its stake in Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the period. Archer Investment Corp grew its holdings in Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 87 shares in the last quarter. Binnacle Investments Inc increased its position in shares of Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 88 shares during the period. Finally, EPG Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 2.0% in the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 89 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $122.74 on Friday. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company has a market capitalization of $152.28 billion, a P/E ratio of 19.03, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a fifty day moving average of $123.04 and a 200-day moving average of $116.97.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the insider directly owned 106,221 shares of the company’s stock, valued at $12,958,962. This trade represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 136,257 shares of company stock worth $16,855,192 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Mizuho boosted their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Truist Financial initiated coverage on Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. Scotiabank started coverage on Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Finally, Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $131.68.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.